Polygonatum Cepa


Uriel Pharmacy Inc.
Human Otc Drug
NDC 48951-8358
Polygonatum Cepa is a human otc drug labeled by 'Uriel Pharmacy Inc.'. National Drug Code (NDC) number for Polygonatum Cepa is 48951-8358. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Polygonatum Cepa drug includes Barium Citrate - 12 [hp_X]/g Bos Taurus Cartilage - 10 [hp_X]/g Bos Taurus Placenta - 8 [hp_X]/g Copper - 8 [hp_X]/g Echinacea Angustifolia - 2 [hp_X]/g Gold - 8 [hp_X]/g Graphite - 17 [hp_X]/g Hirudin - 4 [hp_X]/g Onion - 2 [hp_X]/g Polygonatum Cyrtonema Root - 4 [hp_X]/g and more. The currest status of Polygonatum Cepa drug is Active.

Drug Information:

Drug NDC: 48951-8358
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Polygonatum Cepa
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Polygonatum Cepa
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Uriel Pharmacy Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Gel
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BARIUM CITRATE - 12 [hp_X]/g
BOS TAURUS CARTILAGE - 10 [hp_X]/g
BOS TAURUS PLACENTA - 8 [hp_X]/g
COPPER - 8 [hp_X]/g
ECHINACEA ANGUSTIFOLIA - 2 [hp_X]/g
GOLD - 8 [hp_X]/g
GRAPHITE - 17 [hp_X]/g
HIRUDIN - 4 [hp_X]/g
ONION - 2 [hp_X]/g
POLYGONATUM CYRTONEMA ROOT - 4 [hp_X]/g
SILICON DIOXIDE - 8 [hp_X]/g
SILVER - 12 [hp_X]/g
SUS SCROFA SKIN - 8 [hp_X]/g
THUJA OCCIDENTALIS WHOLE - 8 [hp_X]/g
VESPA CRABRO - 6 [hp_X]/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Sep, 2009
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 09 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Uriel Pharmacy Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:M0005152
N0000175831
N0000008595
N0000008924
N0000175830
N0000185508
N0000175629
N0000184306
M0000728
N0000185371
M0006342
M0022575
N0000185364
N0000185001
N0000185377
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:J9X0Y34WC2
UE77B10IIY
83AL37E3A7
789U1901C5
VB06AV5US8
79Y1949PYO
4QQN74LH4O
MNY7X23SRZ
492225Q21H
W93B56AH6R
ETJ7Z6XBU4
3M4G523W1G
3EM4VW6TQN
5HBV6WCE3N
K3ALM8S49H
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Copper-containing Intrauterine Device [EPC]
Standardized Chemical Allergen [EPC]
Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Animal Skin Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Decreased Embryonic Implantation [PE]
Decreased Sperm Motility [PE]
Inhibit Ovum Fertilization [PE]
Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Increased IgG Production [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Copper [CS]
Allergens [CS]
Dietary Proteins [CS]
Vegetable Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Cells
Epidermal [EXT]
Copper [CS]
Copper-containing Intrauterine Device [EPC]
Decreased Embryonic Implantation [PE]
Decreased Sperm Motility [PE]
Dietary Proteins [CS]
Increased Histamine Release [PE]
Increased IgG Production [PE]
Inhibit Ovum Fertilization [PE]
Non-Standardized Animal Skin Allergenic Extract [EPC]
Non-Standardized Food Allergenic Extract [EPC]
Standardized Chemical Allergen [EPC]
Vegetable Proteins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
48951-8358-560 g in 1 TUBE (48951-8358-5)01 Sep, 2009N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Uses: promotes skin regeneration and minimizes scars.

Product Elements:

Polygonatum cepa polygonatum cepa tea tree oil sorbic acid water glycerin sodium alginate rosemary oil citrus paradisi seed onion onion echinacea angustifolia echinacea angustifolia hirudin hirudin polygonatum cyrtonema root polygonatum cyrtonema root vespa crabro vespa crabro gold gold bos taurus cartilage bos taurus cartilage copper copper sus scrofa skin sus scrofa skin bos taurus placenta bos taurus placenta silicon dioxide silicon dioxide thuja occidentalis whole thuja occidentalis whole silver silver barium citrate barium graphite graphite

Indications and Usage:

Directions: for topical use only

Warnings:

Warnings: for external use only. claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. do not use if allergic to any ingredient. consult a doctor before use for serious conditions, if conditions worsen or persist, or accidental ingestion occurs. if pregnant or nursing, consult a doctor before use. avoid contact with eyes. do not use if safety seal is broken or missing.

Dosage and Administration:

Apply to skin as needed. under age 2: consult a doctor.

Package Label Principal Display Panel:

Polygonatum cepa gel

Further Questions:

Questions? call 866.642.2858 made with care by uriel, east troy, wi 53120 www.urielpharmacy.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.